Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

N/ACompletedNCT01926990

Stanford University19 enrolled

Overview

This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Renal Cell Cancer

Interventions

perfusion computed tomographyDEVICE

Undergo perfusion CT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Suspected or biopsy-proven renal cell carcinoma * Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Serum creatinine greater than or equal to 1.7 mg/dL * Severe allergy to contrast agent * Any contraindication for undergoing a CT scan * Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential

Locations (1)

Stanford University Cancer Institute

Stanford, California, United States

Outcomes

Primary Outcomes

Characterization of the relationship between Change in blood flow measured through perfusion CT techniques and Change in tumor size measured through non-investigational CT

Time frame: 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication

Secondary Outcomes

Characterization of the relationship between change in perfusion CT measurements (eg. Mean transit time) and change in tumor size measured by non-investigational CT

Time frame: 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication

Relationship between change in blood flow and tumor response measured on ordinal scale

Time frame: 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication

Relationship between change in blood flow at Day 8 and change in tumor size measured on continuous scale at Week 12 and tumor response measured on ordinal scale at Week 12

Time frame: 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication

Relationship between change in blood flow at Day 8 and at Week 12 and progression-free survival

Time frame: 12 weeks after start of standard systemic targeted therapy medication

Relationship between change in blood flow at Day 8 and at Week 12 and time to nadir of tumor size

Time frame: 12 weeks after start of standard systemic targeted therapy medication

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.